- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
NICE recommends five new therapies
27 January 2016 • Author: Victoria White
The National Institute for Health and Care Excellence (NICE) has published its final recommendations on whether six different drug treatments should be routinely funded by the NHS.
Of the six treatments assessed, NICE recommended five:
- NICE recommends AstraZeneca’s Lynparza (olaparib) for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube and peritoneal cancer. The drug is for cancers in adults who have tested positive for the BRCA1 or BRCA2 mutations, and whose disease has responded to platinum-based chemotherapy.
- NICE also recommends Bayer’s Zofigo (radium 223 dichloride) as an option for treating adults with hormone relapsed prostate cancer, who have previously received docetaxel treatment, are experiencing symptoms from the disease spreading to their bones, and have no signs of cancer in any other organ.
- In addition, NICE recommends another prostate cancer treatment – Astellas’ Xtandi (enzalutamide). It is recommended as an option for treating people with metastatic hormone-relapsed prostate cancer who have no or mild symptoms after androgen deprivation treatment has stopped working, and before chemotherapy is needed.
- Another recommendation is Novartis’ Farydak (panobinostat) as a possible treatment for people with multiple myeloma if they have had at least two prior therapies (including bortezomib and an immunomodulatory agent).
- The final recommendation is for Boehringer Ingelheim’s Ofev (nintedanib) for some people with idiopathic pulmonary fibrosis (IPF).
However, NICE does not recommend Lilly’s Cyramza (ramucirumab) for people whose stomach cancer has spread or if they have cancer that develops at the point where the food pipe joins to the stomach. The independent appraisal committee concluded that ramucirumab does not provide enough benefit to patients to justify its high cost and did not qualify for end of life considerations, so it was not recommended.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics